These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9547132)

  • 61. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Hollander E; Baldini Rossi N; Sood E; Pallanti S
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Escitalopram prevents relapse of obsessive-compulsive disorder.
    Fineberg NA; Tonnoir B; Lemming O; Stein DJ
    Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
    Zarate CA; Kando JC; Tohen M; Weiss MK; Cole JO
    J Clin Psychiatry; 1996 Feb; 57(2):67-71. PubMed ID: 8591971
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline.
    Dodt JE; Byerly MJ; Cuadros C; Christensen RC
    Am J Psychiatry; 1997 Apr; 154(4):582. PubMed ID: 9090357
    [No Abstract]   [Full Text] [Related]  

  • 73. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome.
    Sallee FR; Richman H; Beach K; Sethuraman G; Nesbitt L
    J Am Acad Child Adolesc Psychiatry; 1996 Dec; 35(12):1647-56. PubMed ID: 8973072
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.
    Levy DM; Arush OB; Carmi L; Wetzler AJ; Zohar J
    Compr Psychiatry; 2024 Aug; 133():152486. PubMed ID: 38703743
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
    Mowla A; Baniasadipour H
    Int Clin Psychopharmacol; 2023 Jan; 38(1):4-8. PubMed ID: 35695582
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sertraline and mental retardation with obsessive-compulsive disorder.
    Wiener K; Lamberti JS
    Am J Psychiatry; 1993 Aug; 150(8):1270. PubMed ID: 8328577
    [No Abstract]   [Full Text] [Related]  

  • 78. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.